Trial
NCT01203943
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Celgene
Collaborators
—
Condition
Idiopathic Pulmonary Fibrosis
Intervention
CC-930
Why stopped
The benefit/ risk profile does not support continuation of this study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-11-19